A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial

(2013) Diana Crivellari et al.   BREAST

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study

(2013) M.E. Hamaker et al.   BREAST

Analysis of docetaxel therapy in elderly (⩾70years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study

(2013) F.L. Gerritse et al.   EUROPEAN JOURNAL OF CANCER

End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology Position Article

(2013) Hans Wildiers et al.   JOURNAL OF CLINICAL ONCOLOGY

1st International consensus guidelines for advanced breast cancer (ABC 1)

(2012) F. Cardoso et al.   BREAST

Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

(2012) Laura Biganzoli et al.   LANCET ONCOLOGY

Chemotherapy treatment for older women with metastatic breast cancer: What is the evidence?

(2011) Marc Debled et al.   CANCER TREATMENT REVIEWS

Moderate dose capecitabine in older patients with metastatic breast cancer: A standard option for first line treatment?

(2010) A.A. Kotsori et al.   BREAST